Investors

Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:

3 patent-pending new drug families drawing on novel chemical structures;

75 compounds synthesized with preclinical data demonstrating promising results; and

Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Stock Quote

Press Releases & News

Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

March 30, 2021

Read More

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set

March 23, 2021

Read More

Mindset Pharma Announces $5 Million Bought Deal Financing

March 22, 2021

Read More